Cannara Biotech approved for DTC electronic clearing

Mr. Nicholas Sosiak reports CANNARA ANNOUNCES DTC ELIGIBILITY TO FACILITATE U.S. INVESTOR ACCESS AND STRENGTHENS BALANCE SHEET THROUGH COMPLETION OF DEBT-TO-EQUITY CONVERSION Cannara Biotech Inc.'s common shares of the company are now eligible for electronic clearing and settlement in the United States through the Depository Trust Company (DTC). DTC eligibility will expand access and reduce costs for U.S. investors purchasing Cannara shares enhancing Cannara's trading liquidity. As a subsidiary of the Depository Trust & Clearing Corp., DTC facilitates the electronic clearing and settlement of publicly traded securities in the United States. With this eligibility, the company's shares can now be traded through a wider network of U.S. brokerage firms, enabling faster transactions and broader market access. "Achieving DTC eligibility marks an important milestone in our capital markets strategy," commented Zohar Krivorot, founder and chief executive officer of Cannara Biotech. "This step makes it easier for American investors to trade our shares, broadens our potential shareholder base and further enhances Cannara's visibility in the United States as the industry positions itself for potential federal regulatory reform." Completion of Olymbec share issuance Further to its news release dated Oct. 2, 2025, the company is also pleased to announce the completion of the issuance of 3,462,763 common shares to Olymbec Investments Inc. at an issue price of $1.80 per share, in full payment of approximately $6.2-million of indebtedness, consisting of $4.7-million in principal and approximately $1.5-million in accrued interest, under its convertible debenture issued to Olymbec, the proceeds of which were used to purchase Cannara's megaproduction facility in Valleyfield, Que. "The Olymbec share issuance, triggered by Olymbec under the terms of the debenture, further reduces our debt leverage and interest obligations while preserving liquidity to support the execution of our long-term growth strategy," said Nicholas Sosiak, chief financial officer of Cannara Biotech. "The transaction is expected to strengthen Cannara's balance sheet and enhance our financial flexibility. We would like to thank Olymbec for their continued confidence and historical support of Cannara." Clarification regarding options granted in connection with investor relations services Further to the company's press release dated Oct. 2, 2025, the company wishes to clarify that the 40,000 stock options granted to Bristol Capital Ltd. on April 25, 2025, will expire 48 months from the date of grant. Accordingly, the options will expire on April 25, 2029 (and not April 25, 2028, as previously stated). All other terms remain unchanged. About Cannara Biotech Inc. Cannara Biotech is a vertically integrated producer of affordable premium-grade cannabis products for the Canadian markets. Cannara owns two megafacilities based in Quebec spanning over 1.65-million square feet, providing the company with 100,000 kilograms of potential annualized cultivation output. Leveraging Quebec's low electricity costs, Cannara's facilities produce premium-grade cannabis products at an affordable price. We seek Safe Harbor.